Emerging trends in pharmacological treatment of inferior alveolar nerve sensory disorders: a scoping review.

BACKGROUND

Sensory disorders of the inferior alveolar nerve, often arising from dental procedures, markedly impact the quality of life of patients. This article proposes a scoping review to analyze emerging trends in pharmacological treatment for these disorders, addressing scientific gaps and clinical practices.

MATERIAL AND METHODS

The review followed the PRISMA-ScR protocol, conducting data searches across various databases, including PubMed and Cochrane, until March 2024. Case studies and series related to patients with sensory disorders of the inferior alveolar nerve undergoing pharmacological treatment were included.Parte inferior do formulário Results: Out of the initial 542 records, 7 studies were included after rigorous selection, displaying low bias risk. Medicinal therapies varied, encompassing analgesics, corticosteroids, anesthetics, and vitamin complexes. Dipyrone stood out in the preoperative phase, while prednisone proved effective in paresthesias. Selegiline, an MAO-B inhibitor, introduced an innovative approach.

CONCLUSIONS

Agents such as selegiline offer an innovative approach to sensory restoration, while corticosteroids exhibit variable efficacy. Dipyrone is effective in preoperative pain control, and vitamin complexes provide regenerative and neuroprotective benefits. However, it is essential to consider that treatment success may vary and to address the individual needs of patients.